How to Invest in Biotech Companies

Biotech attracts investors with a simple promise and a hard reality. The promise is that a single approved therapy can be worth billions. The reality is that most candidates fail, the failures are often total, and the timelines are measured in years. Investing well in this sector is less about picking winners and more about understanding a specific kind of risk. This essay is a plain-language primer on how biotech investing works. It is educational and is not investment advice.

Two ways to invest, two different games

There are two broad routes into biotech. The public route means buying shares of companies listed on an exchange, either individually or through sector funds that hold a basket of names. The private route means investing in companies before they are public, through venture capital, which is largely the domain of professional funds and accredited investors. The two behave differently. Public biotech is liquid and volatile, with prices that swing on trial readouts and regulatory news. Private biotech is illiquid and long-horizon, with value that is hard to mark until a financing, an approval, or an acquisition sets a price. Knowing which game you are playing is the first decision, and the mechanics of the private side are covered in the guide to healthcare venture capital.

The risk is binary and the base rates are humbling

The defining feature of biotech is binary clinical risk. A drug either works in its pivotal trial or it does not, and the gap between those outcomes can erase or create most of a company's value in a single morning. The base rates explain the caution. An analysis of thousands of development programs found that the probability of a drug moving from the first phase of human testing all the way to approval is in the low double digits across all diseases, and lower in oncology (Wong, Siah, and Lo, 2019). Earlier work reached similar conclusions, with success rates that fall sharply at each phase transition (Hay et al., 2014). The companion piece on why biotech startups fail walks through where programs most often break.

What you are actually underwriting

When you invest in a biotech company, you are not buying current earnings, because most have none. You are buying a probability-weighted claim on a future product. That means the real analysis is about three things: the strength of the science, the quality of the team, and the regulatory and commercial path. The capitalized cost of bringing a single drug to market has been estimated at roughly 2.6 billion dollars in 2013 terms, which tells you how much capital a program will consume before it can return anything (DiMasi, Grabowski, and Hansen, 2016). An investment thesis that ignores how much money a company will need, and on what terms it will raise that money, is incomplete no matter how good the science looks.

Why regulatory strategy matters as much as the molecule

A common error is to evaluate the science and stop there. In biotech, the regulatory path often determines value more than the underlying biology. A strong molecule on an unclear or unusually expensive approval pathway can be worth less than a modest molecule on a clean one. The structure of that pathway, including the difference between drug and biologic routes, is laid out in the founder's guide to the FDA approval process. For investors, reading a company's regulatory strategy, the clarity of its endpoints, the design of its trials, and its history of interactions with regulators, is as important as reading its science.

Diversification is not optional

Because outcomes are binary and base rates are low, concentration in a single biotech name is a high-variance bet that can go to zero on one trial. This is why both professional and individual investors in the sector tend to diversify, whether across many private positions in a fund or across many public names in a sector index. The logic is the same as in venture capital generally: returns are driven by a small number of large winners, so the portfolio must be wide enough to contain one. A single position should be sized as if it might fail completely, because in this sector that is a routine outcome rather than a remote one.

Time horizon and the cost of being early

Biotech rewards patience and punishes the need for quick liquidity. Drug development runs for years, and even a successful program can spend a long stretch with no value-creating events between trials. Investors who may need their capital back on a short schedule are poorly matched to the sector's rhythm. Being right too early, and being forced to sell during a long quiet period or a sector downturn, produces losses that have nothing to do with whether the science eventually works. Matching the holding period to the development timeline is part of the discipline.

A grounded way to approach the sector

The honest summary is that biotech can reward investors who understand its specific risk and ruin those who treat it like an ordinary growth sector. The useful habits are consistent: respect the base rates, weight regulatory strategy heavily, size positions for total loss, and match your horizon to the science. The underlying biology that these companies are built on, at an educational level, is surveyed in the cancer research library. For how this judgment has been applied across decades of building and backing healthcare companies, see the professional biography and the advisory practice.